Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Authors: Warren Fiskus, Naval Daver, Steffen Boettcher, Christopher P. Mill, Koji Sasaki, Christine E. Birdwell, John A. Davis, Kaberi Das, Koichi Takahashi, Tapan M. Kadia, Courtney D. DiNardo, Francis Burrows, Sanam Loghavi, Joseph D. Khoury, Benjamin L. Ebert, Kapil N. Bhalla

Published: 2022-09-23

DOI: 10.1038/s41375-022-01707-w

Source: Full article

---

Abstract

No abstract found.